Treatment of epidemic (AIDS-related) Kaposi's sarcoma

Current Opinion in Oncology

Volumn 9, Issue 5, 1997, Pages 433-439

  Jie, Cai ^a   Tulpule, Anil ^a   Zheng, Tong ^a   Masood, Rizwan ^a   Espina, Byron ^a   Gill, Parkash S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; BASIC FIBROBLAST GROWTH FACTOR; BLEOMYCIN; CYTOTOXIC AGENT; DACARBAZINE; DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FUMAGILLOL CHLOROACETYLCARBAMATE; GROWTH FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; LIPOSOME; PACLITAXEL; RETINOID; TECOGALAN; THALIDOMIDE; VASCULOTROPIN; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AUTOCRINE EFFECT; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CHILL; CLINICAL TRIAL; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LEUKOPENIA; LYMPHEDEMA; MAJOR CLINICAL STUDY; META ANALYSIS; MORBIDITY; MORTALITY; MUCOSA INFLAMMATION; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; RIGOR; VISCERA;

EID: 0030880675     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199709050-00007     Document Type: Review

References (38)

1. Gill PS, Hamilton A, Naidu Y: Epidemic (AIDS-related) Kaposi's sarcoma: epidemiology, pathogenesis and treatment AIDS Updates 1994, 7:1-11.
2. Masood R, Cai J, Zheng T, Smith DL, Naidu Y, Gill PS: Vascular endothelial growth factor (vascular permeability factor (VEGF/VPF) is an autocrine growth factor for AIDS-KS. Proc Natl Acad Sci USA 1997, 94:979-984. One of the first reports demonstrating that VEGF stimulates the growth of AIDS-related KS via receptors expressed on KS cells. It is also the first demonstration of this angiogenic factor acting as an autocrine factor in any human tumor.
3. Russell Jones R, Spaull J, Spry C, Wilson Jones E: Histogenesis of Kaposi's sarcoma in patients with and without acquired immunodeficiency syndrome. J Clin Pathol 1986, 39:742-749.
4. Vogel J, Hinrichs SH, Reynolds RK, Luciw PA, Jay G: The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. Nature 1988, 335:606-611.
5. Cai J, Zheng T, Lotz M, Zhang Y, Masood R, Gill PS: Glucocorticoids enhance AIDS-related Kaposi's sarcoma growth through inhibition of TGF-B. Blood 1997, 89:1491-1500. This study elucidates the observed clinical enhancement of KS cell growth due to glucocorticoids, showing regulation of transforming growth factor-β (TGF-β) activation.
6. Chak LY, Gill PS, Levine AM, Meyer PR, Anselmo JA, Petrovich Z: Radiation therapy for acquired immunodeficiency syndrome related Kaposi's sarcoma. J Clin Oncol 1988, 62:735-739.
7. Gill PS, Lunardi-Iskandar Y, Louie S, Tulpule A, Zheng T, Espina BM, Besnier JM, Hermans P, Levine AM, Gallo RC: Human chorionic gonadotropin has antitumor activity in AIDS-related Kaposi's sarcoma. N Engl J Med 1996, 335:1261-1269. Reports of antitumor activity with intralesional human chorionic gonadotropin (hCG) in patients with AIDS-related KS. Differences in the activity of available commercial hCG preparations were found. The mechanism of antitumor activity with hCG appears to be via apoptosis.
8. Groopman JE, Gottlieb MS, Goodman J, Mitsuyasu RT, Conant MA, Prince H, Fahey JL, Derezin M, Weinstein WM, Casavante C, et al.: Recombinant alpha-2 interferon for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med 1984, 100:671-676.
9. Volbering PA, Abrams DI, Conant M, Kaslow K, Vranizan K, Ziegler J: Vinblastine therapy for Kaposi's sarcoma in acquired immunodeficiency syndrome. Ann Intern Med 1985, 103:335-338.
10. Mintzer D, Real FX, Jovina L, Krown SE: Treatment of Kaposi's sarcoma and thrombocytopenia with vincristine in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1985, 102:200-202.
11. Kaplan L, Abrams D, Volberding P: Treatment of Kaposi's sarcoma in acquired immunodeficiency syndrome with an alternating vincristine vinblastine regimen. Cancer Treat Rep 1986, 70:1121-1122.
12. Lassoued SC, Claurel JP, Katlama C, Janier M, Picard C, Matherson S Treatment of acquired immunodeficiency syndrome related Kaposi's sarcoma with bleomycin as a single agent. Cancer 1990, 66;189:1869-1872.
13. Remick SC, Reddy M, Herman D, Grace C, Harper G, Willis K, Candon B, Norton J, Ruckdeschel JC: Continuous infusion bleomycin in AIDS-related Kaposi's sarcoma. J Clin Oncol 1994, 12:1130-1136.
14. Gill PS, Rarick MU, McCutchan JA, Slater L, Parker B, Muchmore E, Bernstein-Singer M, Akil B, Espina BM, Krailo M, et al.: Systemic treatment of AIDS-related Kaposi's sarcoma: results of a randomized trial. Am J Med 1991, 19:427-433.
15. Laubenstein LJ, Krigel RL, Odajnuk CM, Hymes KB, Friedman-Kien A, Wernz JC, Muggia FM: Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine. J Clin Oncol 1984, 2:1115-1120.
16. Gelmann EP, Longo DL, Lane HL, Fauci AS, Masur H, Wesley M, Preble OT, Jacob J, Steis R: Combination chemotherapy of disseminated Kaposi's sarcoma in patients with the acquired immunodeficiency syndrome. Am J Med 1987, 82:456-459.
17. Gill PS, Miles SA, Mitsuyasu RT, Montgomery T, McCarthy S, Espina BM, Feldstein M, Levine AM: Phase I AIDS clinical trials group (075) study of adriamcyin, bleomycin, and vincristine chemotherapy with zidovudine in the treatment of AIDS related Kaposi's sarcoma. AIDS 1994, 8:1695-1699.
18. Gill PS, Mitsuyasu RT, Montgomery T, Huang J, Cabriales S, Testa M, Espina BM, Levine AM, Miles SA: AIDS clinical trials group study 094: a phase I/II trial of ABV chemotherapy with zidovudine and recombinant human GM-CSF in AIDS-related Kaposi's sarcoma. Cancer 1997, in press.
19. Mitsuyasu RT, Gill PS, Paredes J, Ratner L, Remick S, Testa M: Combination chemotherapy, Adriamycin, bleomycin, vincristine (ABV) with dideoxyinosine (ddl) or dideoxycytidine (ddC) in advanced AIDS-related Kaposi's sarcoma (ACTG-163). Proc ASCO 1995, 14:289.
20. Gill PS, Rarick MU, Bernstein-Singer, Harb M, Espina B, Shaw V, Levine AM: Treatment of advanced Kaposi's sarcoma using a combination of bleomycin and vincristine. Am J Clin Oncol 1990, 13:315-319.
21. Masood R, Husain SR, Rahman A, Gill PS: Potentiation of cytotoxicity of Kaposi's sarcoma related to immunodeficiency syndrome (AIDS) by liposome encapsulated doxorubicin. AIDS Res Hum Retrovirus 1993, 8:741-745.
22. Gabizon A: Selective tumour localization and improved therapeutic index of anthracyclines in long circulating liposomas. Cancer Res 1992, 52:1891-1896.
23. Gill PS, Espina BM, Cabriales S, Tulpule A, Esplin JA, Liebman HR, Forrsen E, Ross ME, Levine AM: A phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin (Daunoxome) in the treatment of advanced AIDS-related Kaposi's sarcoma. J Clin Oncol 1995, 13:996-1003.
24. Presant CA, Scolaro M, Kennedy P, Blayney DW, Flanagan B, Lisak JW, Presant J: Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. Lancet 1993, 341:1242-1243.
25. Girard P-M, Bouchaud O, Goetschel A, Mukwaya G, Eestermans G, Michael R, Rozenbaum W, Saimot A-G: Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi's sarcoma. AIDS 1996, 10:753-757. This study reports antitumor efficacy with DaunoXome in patients with AIDS-related Kaposi's sarcoma.
26. Harrison M, Tomlinson D, Stewart S: Liposomal entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol 1995, 13:914-920.
27. Gill PS, Wenrz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn J, Jacobs M, Kempin S, Silbverberg I, Gonzales G, Rarick MU, Myers AM, Shepard F, Sawka C, Pike MC, Ross ME: Randomized phase II trial of liposomal daunorubicin (DaunoXome) versus doxorubicin, bleomycin, vincristine (ABV) in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996, 14:2353-2364. The results of a large pivotal randomized trial in patients with AIDS-related KS, showing similar efficacy between DaunoXome and ABV, But reduced toxicity for DaunoXome.
28. Northfelt DW, Dezube BJ, Thommes JA, Levine R, Von Roenn JH, Dosik GM, Rios A, Krown SE, DuMond C, Mamelok RD: Efficacy of pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 1997, 15:653-600. This study reports antitumor activity of Doxil in patients with relapsed/refractory AIDS-related KS.
29. Saville MW, Leitzau J, Pluda JM, Feuerstein I, Odom J, Wilson WH, Humphrey RW, Feigal E, Steinberg SM, Broder S, et al.: Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet 1995, 346:26-28.
30. Gill PS, Scadden DT, Groopman J, Tulpule A, Hajdenberg J, Mocharnuk, Espina BM, Ilaw M, Bresnahan J, Cabriales S, et al.: Low dose paclitaxel (Taxol) is highly effective in the treatment of patients with advanced AIDS-related Kaposi's sarcoma [abstract 77]. J Acq Immune Defic Syndr Hum Retrovirol 1997, 14:A35.
31. Gill PS, Kidane S, Tulpule A, Espina BM, Masuo K, Sobel RS; A phase I study of DS-4152, a novel angiogenesis inhibitor in the treatment of AIDS-related Kaposi's sarcoma [abstract]. 8th NCI-EORTC symposium on new drugs in cancer therapy. Amsterdam 1994, March 15-18.
32. Dezube BJ, Von Roenn JH, Holden-Wiltse J, Remick S, Cooley TP, Cheuyng TW, Sommadossi JP, Shriver SL, Suckow CW, Gill PS: Fumagillin analog (TNP-470) in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group Study [abstract 78]. J Acq Immune Defic Syndr Hum Retroviral 1997, 14:A35.
33. Louie S, Cai J, Law R, Lin G, Lunardi-Iskandar Y, Jung B, Masood R, Gill PS: The effect of interleukin-1 and interleukin-1 antagonist in AIDS-Kaposi's sarcoma. J Acq Immune Del Syndr Hum Retrovirus 1995, 4:455-460.
34. Miles SA, Rezai AR, Salazar-Gonzales JF, Meyden MV, Stevens RH, Logan DM, Mitsuyasy RT, Taga T, Hirano T, Kishimoto T, et al.: AIDS-Kaposi's sarcoma derived cells produce and respond to interleukin-6. Proc Natl Acad Sci U S A 1990, 87:4068.
35. Nagpal S, Cai J, Zheng T, Patel S, Masood R, Lin GY, Friant S, Johnson A, Chandraratna RAS, Gill PS: Retinoid antagonism of NF-IL-6: insight into the mechanism of anti-proliferative effects of retinoids in Kaposi's sarcoma. Molec Cell Biol 1997, 17:4159-4168. An elucidation of the inhibitory mechanism of action of retinoids in KS. This is the first report to show that retinoids inhibit IL-6 by functional antagonism of NF-IL-6.
36. Bonhomme L, Fredj, Averous S, Saekely AM, Ecstein E, Trumbic B, Meyer P, Lang JM, Misset LK, Jasmin C: Topical treatment of epidemic Kaposi's sarcoma with all trans retinoic acid. Ann Oncol 1991, 2:234-235.
37. Gill PS, Espina BM, Moudgil T, Kidane S, Esplin JA, Tulpule A, Levine AM: All-rrans retinoic acid for the treatment of AIDS-related Kaposi's sarcoma: results of a pilot phase II study. Leukemia 1995, 8:S26-S32.
38. Ganem D, Kedes DH, Operskalski E, Busch M, Kohn R, Flood J, Ganem D: The seroepidemiology of human herpes virus 8 (Kaposi's sarcoma associated herpes virus): distribution of infection in KS risk groups and evidence for sexual transmission. Nature Med 1996, 2:918-924